metformin + prednisone

Metformin + prednisone is a non-branded combination of two well-established pharmaceutical agents, each with distinct mechanisms and clinical uses. Metformin is an oral antidiabetic agent in the biguanide class, primarily used to manage type 2 diabetes by improving insulin sensitivity, decreasing hepatic glucose production (gluconeogenesis), and increasing peripheral glucose uptake. Its main mechanism involves inhibition of mitochondrial complex I and activation of AMP-activated protein kinase (AMPK), leading to reduced blood glucose levels[6][1]. Prednisone is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive properties, commonly prescribed for various inflammatory and autoimmune conditions. It acts as an agonist at the glucocorticoid receptor, modulating gene expression to suppress inflammation[1][8]. When used together, metformin can help mitigate the hyperglycemic side effects induced by prednisone or other systemic glucocorticoids—a benefit supported by randomized controlled trials showing that metformin prevents increases in blood glucose during glucocorticoid therapy without compromising anti-inflammatory efficacy[7][5][1]. This combination does not represent a fixed-dose product but rather concurrent use of both drugs for specific clinical scenarios such as steroid-induced hyperglycemia or metabolic complications.